Godman, B., Bucsics, A., Bonanno, P. Vella, et al., “Barriers for Access to New Medicines: Searching for the Balance between Rising Costs and Limited Budgets,” Front Public Health 6 (2018): 328; M.A. Mousnad, A.A. Shafie, and M.I. Ibrahim, “Systematic Review of Factors Affecting Pharmaceutical Expenditures,” Health Policy 116, nos. 2-3 (2014): 137-146; M. García-Goñi, “Rationalizing Pharmaceutical Spending,” IMF Working Papers 190 (2022): A001.CrossRefGoogle Scholar

Id. (García-Goñi).Google Scholar

Vargas, V., Rama, M., and Singh, R., “Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation Across Diverse Models,” World Bank, 2022.CrossRefGoogle Scholar

Vondeling, G.T., Cao, Q., Postma, M.J., and Rozenbaum, M.H., “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review,” Applied Health Economics and Health Policy 16, no. 5 (2018): 653–660; A.J. Trujillo, J.C. Gutierrez, E.E. Garcia Morales, M. Socal, J. Ballreich, and G. Anderson, “Trajectories of Prices in Generic Drug Markets: What Can We Infer from Looking at Trajectories Rather Than Average Prices?” Health Economics Review 12, no. 1 (2022): 37.CrossRefGoogle ScholarPubMed

Blackstone, E.A. and Joseph, P.F., “The Economics of bBiosimilars,” American Health Drug Benefits 6, no. 8 (2013): 469–478.Google Scholar

Colgan, S., Faasse, K., Martin, L.R., Stephens, M.H., Grey, A., and Petrie, K.J., “Perceptions of Generic Medication in the General Population, Doctors and Pharmacists: A Systematic Review,” BMJ Open 5, no. 12 (2015): e008915; E. Leonard, M. Wascovich, S. Oskouei, P. Gurz, and D. Carpenter, “Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review,” Journal of Managed Care and Specialty Pharmacy 25, no. 1 (2019): 102-112; S.S. Dunne and C.P. Dunne, “What Do People Really Think of Generic Medicines? A Systematic Review and Critical Appraisal of Literature on Stakeholder Perceptions of Generic Drugs,” BMC Medicine 13 (2015): 173.Google ScholarPubMed

Id.; Sarnola, K., Merikoski, M., Jyrkkä, J., and Hämeen-Anttila, K., “Physicians’ Perceptions of the Uptake of Biosimilars: A Systematic Review,” BMJ Open 10, no. 5 (2020): e034183; M.A. Hassali, A.A. Shafie, S. Jamshed, M.I. Ibrahim, and A. Awaisu, “Consumers’ Views on Generic Medicines: A Review of the Literature,” International Journal of Pharmacy Practice 17, no. 2 (2009): 79-88; A. Alrasheedy, M.A. Hassali, and K. Stewart, et al., “Patient Knowledge, Perceptions, and Acceptance of Generic Medicines: A Comprehensive Review of the Current Literature,” Patient Intelligence 6 (2014): 1-29; E.-L. Toverud, K. Hartmann, and H. Håkonsen, “A Systematic Review of Physicians’ and Pharmacists’ Perspectives on Generic Drug Use: What Are the Global Challenges?” Applied Health Economics and Health Policy 13, no. 1 (2015): 35-45.CrossRefGoogle ScholarPubMed

Pan American Health Organization, Regulatory Systems Strengthening in the Americas: Lessons learned from the National Regulatory Authorities of Regional Reference, Pan American Health Organization, 2022.Google Scholar

IQVIA Institute, “The Global Use of Medicines 2022,” available at <https://www.iqvia.com/-/media/iqvia/pdfs/library/publications/the-global-use-of-medicines-2022.pdf> (last visited July 18, 2023).+(last+visited+July+18,+2023).>Google Scholar

Marin, G.H., “The Argentine Health System: An Analysis Based on Access to Medicines,” Cien Saude Colet 26, no. 11 (2021): 5453–5462.CrossRefGoogle ScholarPubMed

Prada, S.I., Soto, V.E., and Andia, T.S., et al., “Higher Pharmaceutical Public Expenditure After Direct Price Control: Improved Access or Induced Demand? The Colombian Case,” Cost Effectiveness and Resource Allocation 16, no. 1 (2018): 8.CrossRefGoogle ScholarPubMed

Parker, S.W., Saenz, J., and Wong, R., “Health Insurance and the Aging: Evidence from the Seguro Popular Program in Mexico,” Demography 55, no. 1 (2018): 361–386.CrossRefGoogle ScholarPubMed

Ñahui, L., Huillca, M., and Lazo, R., et al., “Peruvian Healthcare System: A Scoping Review,” in OSF2021.Google Scholar

Vicente, G., Calnan, M., Rech, N., and Leite, S., “Pharmaceutical Policies for Gaining Access to High-Priced Medicines: A Comparative Analysis between England and Brazil,” Saúde em Debate 46 (2022).CrossRefGoogle Scholar

Luzes, A.R., Bittencourt, G., Mosegui, G., Viana, C.Md.M., Villar, F.A., and Catao, T.P., “Reflections and Perspectives on Biosimilars in Brazil,” International Journal of Pharmacy and Pharmaceutical Sciences 12, no. 7 (2020): 26–31.Google Scholar

Linderson, M., Rocha, M.S., Silva, Q.Ed.Nd., and Brito, M.A.M., “Panorama Atual Das políticas De Medicamentos genéricos No Brasil: Revisão bibliográfica/Current Overview of Generic Drug Policies in Brazil: Literature Review,” Brazilian Applied Science Review 5, no. 3 (2021): 1342–1354; J.A.Z. Bermudez, J.C.Sd. Costa, J.Cd. Noronha, “Desafíos do Acesso a Medicamentos no Brasil,” FIOCRUZ, 2020.Google Scholar

Ministerio de Salud, Modifica el Código Sanitario en materia de regulación de farmacias y medicamentos, 2014.Google Scholar

Ortiz-Prado, E., Ponce-Zea, J., Vasconez, J.E., et al., “Current Trends for Biosimilars in the Latin American Market,” Generics and Biosimilars Initiative Journal (GaBI Journal) 9, no. 2 (2020): 64–74.Google Scholar

Lizarraga, A. and Mysler, E., “Similar and Mimics: Latin America Biosimilar Regulations,” International Journal of Rheumatic Diseases 22, no. 1 (2019): 6–8; E. Mysler and M. Scheinberg, “Biosimilars in Rheumatology: A View from Latin America,” Clinical Rheumatology 31, no. 9 (2012): 1279-1280.CrossRefGoogle ScholarPubMed

Mysler, E., Pineda, C., Horiuchi, T., et al., “Clinical and Regulatory Perspectives on Biosimilar Therapies and Intended Copies of Biologics in Rheumatology,” Rheumatology International 36, no. 5 (2016): 613–625.CrossRefGoogle ScholarPubMed

Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement,” PLoS Medicine 6, no. 7 (2009): e1000097.CrossRefGoogle ScholarPubMed

Shea, B.J., Reeves, B.C., Wells, G., et al., “AMSTAR 2: A Critical Appraisal Tool for Systematic Reviews That Include Randomised or Non-randomised Studies of Healthcare Interventions, or Both,” BMJ 358 (2017): j4008.CrossRefGoogle ScholarPubMed

Gossell-Williams, M., “Generic Substitutions: A 2005 Survey of the Acceptance and Perceptions of Physicians in Jamaica,” West Indian Medicine Journal 56, no. 5 (2007): 458–463; D. Flood, I. Mathieu, A Chary, P. García, and P. Rohloff, “Perceptions and Utilization of Generic Medicines in Guatemala: A Mixed-Methods Study with Physicians and Pharmacy Staff,” BMC Health Services Research 17, no. 1 (2017): 27.Google ScholarPubMed

Id. (Gossell-Williams).Google Scholar

Flood, et al., supra note 23.Google Scholar

Gossell-Williams, supra note 23.Google Scholar

Flood, et al., supra note 23.Google Scholar

Carvalho, M.C., Accioly, H. Jr., Raffin, F.N., Campos, M.N., Cruz, M.M., Alves, M.K., “[Social Representations of Generic Drugs by Pharmacists: Determination of the Central and Peripheral Representational Systems],” Cadernos de Saude Publica. 21, no. 1 (2005): 226–234.Google ScholarPubMed

Flood, et al., supra note 23.Google Scholar

Id. Google Scholar

da Rocha, C.E., de Barros, J.A., Silva, M.D., “[Knowledge and Information Concerning Generic Drugs in a Public Outpatient Population in Recife, Pernambuco, Brazil],” Cadernos de Saude Publica 23, no. 5 (2007): 1141–1150; E.P. Nardi and M.B. Ferraz, “Perception of the Value of Generic Drugs in São Paulo, Brazil,” Cadernos de Saude Publica 32, no. 2 (2016): e00038715; M.C. Carvalho, H. Accioly Júnior, F.N. Raffin, “Social Representations of Generic Drugs by Consumers from Natal, Rio Grande do Norte, Brazil],” Cadernos de Saude Publica 22, no. 3 (2006): 653-661.Google Scholar

Id. (da Rocha, et al.).Google Scholar

Carvalho, et al., supra note 31.Google Scholar

Nardi and Ferraz, supra note 31.Google Scholar

Id. Google Scholar

Carvalho, et al., supra note 31.Google Scholar

Vosgerau, M.Z., de Souza, R.K., and Soares, D.A., “[Utilization of Generics in an Area Covered by a Family Health Unit in a Southern Brazilian City],” Revista Brasileira de Epidemiologia 14, no. 2 (2011): 253–263; R.B. Goldszmidt, A.R. Buttendorf, G. Schuldt Filho, J.M. Souza, Jr., and M.A. Bianchini, “The Impact of Generic Labels on the Consumption of and Adherence to Medication: A Randomized Controlled Trial,” European Journal of Public Health 29, no. 1 (2019): 12-17; C.N. Monteiro, R.J. Gianini, N.J. Segri, M. Goldbaum, M.B. Barros, and C.L. Cesar, “Use of Generic Drugs in São Paulo City, Brazil, in 2003: A Population-Based Study,” Epidemiology and Health Services 25, no. 2 (2016): 251-258.CrossRefGoogle Scholar

Id. (Monteiro, et al.).Google Scholar

Mendoza-Chuctaya, G., Cubas-Llalle, W.S., Mejia, C.R., et al., “[The Population’s Perceptions of Generic Drugs Compared to Original Brand-Name Drugs in Peruvian Hospitals],” Cadernos de Saude Publica 35, no. 10 (2019): e00065118.CrossRefGoogle ScholarPubMed

Nardi and Ferraz, supra note 31.Google Scholar

Mendoza-Chuctaya, et al., supra note 39.Google Scholar

Nardi and Ferraz, supra note 31.Google Scholar

Goldszmidt, et al., supra note 37.Google Scholar

Monteiro, et al., supra note 37.Google Scholar

Vosgerau, et al., supra note 37.Google Scholar

Faria, M.Ad.S. and Tavares-Neto, J., “Conhecimento popular sobre medicamento genérico em um Distrito Docente-Assistencial do Município de Rio Branco, Estado do Acre, Brasil,” Epidemiologia e Serviços de Saúde 15 (2006): 37–45; C.R. Blatt, S.C. Trauthman, E.H. Schmidt, S. Marchesan, L.M. da Silva, and J.L. Martins, “[General Awareness and Use of Generic Medication among Citizens of Tubarão, State of Santa Catarina, Brazil],” Ciencia & Saude Coletiva 17, no. 1 (2012): 79-87.Google Scholar

Bertoldi, A.D., Barros, A.J., and Hallal, P.C., “Generic Drugs in Brazil: Known by Many, Used by Few,” Cadernos de Saude Publica 21, no. 6 (2005): 1808–1815.CrossRefGoogle ScholarPubMed

Guttier, M.C., Silveira, M.P.T., Luiza, V.L., and Bertoldi, A.D., “Factors Influencing the Preference for Purchasing Generic Drugs in a Southern Brazilian City,” Revista de Saude Publica 51 (2017): 59.CrossRefGoogle Scholar

Lira, C.A., Oliveira, J.N., Mdos, S. Andrade, Vancini-Campanharo, C.R., and Vancini, R.L., “Knowledge, Perceptions and Use of Generic Drugs: A Cross Sectional Study,” Einstein (Sao Paulo) 12, no. 3 (2014): 267–273.CrossRefGoogle ScholarPubMed

Tierling, V.L., Paulino, M.A., Fernandes, L.C., Schenkel, E.P., Mengue, S.S., “Nível de conhecimento sobre a composição de analgésicos com ácido acetilsalicílico,” Revista de Saúde Pública 38, no. 2 (2004).CrossRefGoogle Scholar

See supra note 48-51.Google Scholar

Blatt, et al., supra note 48; Lira, et al., supra note 51.Google Scholar

Nardi, E.P., Ferraz, M.B., Pinheiro, G.R., Kowalski, S.C., Sato, E.I., “Perceptions of the Population Regarding Generic Drugs in Brazil: A Nationwide Survey,” BMC Public Health 15 (2015): 117.CrossRefGoogle ScholarPubMed

Guttier, M.C., Silveira, M.P., Luiza, V.L., and Bertoldi, A.D., “[Perception, Knowledge, and Use of Generic Drugs in Southern Brazil: What Changed from 2002 to 2012?]” Cadernos de Saude Publica 32, no. 7 (2016).Google ScholarPubMed

See supra note 48.Google Scholar

Lira, et al., supra note 51.Google Scholar

Nardi, et al., supra note 55.Google Scholar

See supra note 49 and 50.Google Scholar

Nardi, et al., supra note 55.Google Scholar

Nardi and Ferraz, supra note 33.Google Scholar

Azevedo, V.F., Felippe, L.R., and Machado, D.M., “Opinion of Some Brazilian Rheumatologists about Biosimilars,” Revista Brasileira de Reumatologia 51, no. 6 (2011): 667–671.Google ScholarPubMed

Castañeda-Hernández, G., Sandoval, H., Coindreau, J., Rodriguez-Davison, L.F., and Pineda, C., “Barriers Towards Effective Pharmacovigilance Systems of Biosimilars in Rheumatology: A Latin American Survey,” Pharmacoepidemiology and Drug Safety 28, no. 8 (2019): 1035–1044.CrossRefGoogle Scholar

Reilly, M.S. and Gewanter, H.L., “Prescribing Practices for Biosimilars: Questionnaire Survey Findings from Physicians in Argentina, Brazil, Colombia and Mexico,” Generics and Biosimilars Initiative Journal 4 (2015): 161+.Google Scholar

Azevedo, et al., supra note 61.Google Scholar

Reilly and Gewanter, et al., supra note 63.Google Scholar

Castañeda-Hernández, et al., supra note 62.Google Scholar

Garcia, K.S., Facas, B.P., Machado, M.B., et al., “Biosimilar Knowledge and Viewpoints among Brazilian Inflammatory Bowel Disease Patients,” Therapeutic Advances in Gastroenterology 14 (2021): 17562848211013249.CrossRefGoogle ScholarPubMed

Graham-Clarke, P.L., Hauber, B., Boeri, M., et al., “Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia,” Patient Prefer Adherence 14 (2020): 1049–1064.CrossRefGoogle ScholarPubMed

Colgan, et al., supra note 6.Google Scholar

Toverud, et al., supra note 7.Google Scholar

Dunne and Dunne, supra note 6; id. (Toverud).Google Scholar

Toverud, et al., supra note 7.Google Scholar

Colgan, et al., supra note 6; Dunne and Dunne, supra note 6; Toverud, supra note 7.Google Scholar

Leonard, et al., and Sarnola, et al., both supra note 6.Google Scholar

Jacobs, I., Singh, E., Sewell, K.L., Al-Sabbagh, A., and Shane, L.G., “Patient Attitudes and Understanding about Biosimilars: An International Cross-Sectional Survey,” Patient Preference and Adherence 10 (2016): 937–948; E. van Overbeeke, B. De Beleyr, J. de Hoon, R. Westhovens, and I. Huys, “Perception of Originator Biologics and Biosimilars: A Survey among Belgian Rheumatoid Arthritis Patients and Rheumatologists,” BioDrugs 31, no. 5 (2017): 447-459.CrossRefGoogle ScholarPubMed

Sheperd, J., “Biologic Drugs, Biosimilars, and Barriers to Entry,” Health Matrix Cleveland 25 (2015): 139–611; M.Z. Zhai, A. Sarpatwari, and A.S. Kesselheim, “Why Are Biosimilars Not Living Up to Their Promise in the US?” AMA Journal of Ethics 21, no. 8 (2019): E668-678.Google Scholar